A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood
J E
JE
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892-3017, United States. Ledgerwood@mail.nih.gov
Costner
P
P
Desai
N
N
Holman
L
L
Enama
M E
ME
Yamshchikov
G
G
Mulangu
S
S
Hu
Z
Z
Andrews
C A
CA
Sheets
R A
RA
Koup
R A
RA
Roederer
M
M
Bailer
R
R
Mascola
J R
JR
Pau
M G
MG
Sullivan
N J
NJ
Goudsmit
J
J
Nabel
G J
GJ
Graham
B S
BS
D000260:Adenoviruses, Human / Q000235:genetics*; D000293:Adolescent; D000328:Adult; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D016207:Cytokines / Q000276:immunology; D004311:Double-Blind Method; D046129:Ebola Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D029043:Ebolavirus / Q000235:genetics / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D010919:Placebos / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000276:immunology; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D055815:Young Adult
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D016207:Cytokines; D046129:Ebola Vaccines; D010919:Placebos; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; C113189:envelope glycoprotein, Ebola virus